Generic placeholder image

Current Medicinal Chemistry


ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Mini-Review Article

Discovery and Investigation of 1-[4-(2-Aminoethoxy)Phenylcarbonyl]- 3,5-Bis-(Benzylidene)-4-Piperidones as Candidate Antineoplastic Agents: Our Last 15 Years Study

Author(s): Mohammad Hossain*, Carlos E. Enci, Jonathan R. Dimmock* and Umashankar Das*

Volume 28, Issue 13, 2021

Published on: 30 July, 2020

Page: [2453 - 2464] Pages: 12

DOI: 10.2174/0929867327666200730215752

Price: $65


This review outlines the discovery and development of a novel series of 1-[4-2- aminoethoxy)phenylcarbonyl]-3,5-bis-(benzylidene)-4-piperidones (5-8) as potential drug candidates over the last 15 years in our laboratory. Many of these compounds demonstrate excellent cytotoxic properties and are often more potent than contemporary anticancer drugs. Two highly important features of many of these molecules are first, the greater tumour-selective toxicity and second, the ability of these molecules to act as modulators of multi-drug resistance. The modes of action of some of the potent compounds are by apoptosis induction, generation of reactive oxygen species, activation of certain caspases and affecting mitochondrial functions. These molecules also display promising antimalarial and antimycobacterial properties. In a short term toxicity study, these molecules are well tolerated in mice. Structure-activity relationships and a drug delivery system along with pharmacokinetic studies and metabolic stability of these compounds, have been presented. The positive characteristics associated with the series (5-8) warrant their further evaluations as candidate antineoplastic drug candidates.

Keywords: Piperidones, unsaturated ketones, curcumin, anticancer, cytotoxic, antimalarial, antimycobacterial, multi-drug resistance.

Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2018, 68(6), 394-424.
[] [PMID: 30207593]
López-Lázaro, M. Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. Mol. Nutr. Food Res., 2008, 52(Suppl. 1), S103-S127.
[] [PMID: 18496811]
Liu, W.; Zhai, Y.; Heng, X.; Che, F.Y.; Chen, W.; Sun, D.; Zhai, G. Oral bioavailability of curcumin: problems and advancements. J. Drug Target., 2016, 24(8), 694-702.
[] [PMID: 26942997]
Das, U.; Sharma, R.K.; Dimmock, J.R. 1,5-diaryl-3-oxo-1,4-pentadienes: a case for antineoplastics with multiple targets. Curr. Med. Chem., 2009, 16(16), 2001-2020.
[] [PMID: 19519378]
Dimmock, J.R.; Kandepu, N.M.; Nazarali, A.J.; Motaganahalli, N.L.; Kowalchuk, T.P.; Pugazhenthi, U.; Prisciak, J.S.; Quail, J.W.; Allen, T.M.; LeClerc, R.; Santos, C.L.; De Clercq, E.; Balzarini, J. Sequential cytotoxicity: a theory evaluated using novel 2-[4-(3-aryl-2-propenoyloxy)phenyl-methylene]cyclohexanones and related compounds. J. Med. Chem., 2000, 43(21), 3933-3940.
[] [PMID: 11052798]
Gordillo, G.M.; Biswas, A.; Khanna, S.; Spieldenner, J.M.; Pan, X.; Sen, C.K. Multidrug resistance-associated protein-1 (MRP-1)-dependent glutathione disulfide (GSSG) efflux as a critical survival factor for oxidant-enriched tumorigenic endothelial cells. J. Biol. Chem., 2016, 291(27), 14394.
[] [PMID: 27371570]
Pati, H.N.; Das, U.; Sharma, R.K.; Dimmock, J.R. Cytotoxic thiol alkylators. Mini Rev. Med. Chem., 2007, 7(2), 131-139.
[] [PMID: 17305587]
Hossain, M.; Das, U.; Dimmock, J.R. Recent advances in α,β-unsaturated carbonyl compounds as mitochondrial toxins. Eur. J. Med. Chem., 2019, 183,111687.
[] [PMID: 31539776]
Benvenuto, J.A.; Connor, T.H.; Monteith, D.K.; Laidlaw, J.L.; Adams, S.C.; Matney, T.S.; Theiss, J.C. Degradation and inactivation of antitumor drugs. J. Pharm. Sci., 1993, 82(10), 988-991.
[] [PMID: 8254498]
Dimmock, J.R.; Arora, V.K.; Wonko, S.L.; Hamon, N.W.; Quail, J.W.; Jia, Z.; Warrington, R.C.; Fang, W.D.; Lee, J.S. 3,5-Bis-benzylidene-4-piperidones and related compounds with high activity towards P388 leukemia cells. Drug Des. Deliv., 1990, 6(3), 183-194.
[PMID: 2076179]
Das, U.; Alcorn, J.; Shrivastav, A.; Sharma, R.K.; De Clercq, E.; Balzarini, J.; Dimmock, J.R. Design, synthesis and cytotoxic properties of novel 1-[4-(2-alkylamino-ethoxy)phenylcarbonyl]-3,5-bis(arylidene)-4-piperidones and related compounds. Eur. J. Med. Chem., 2007, 42(1), 71-80.
[] [PMID: 16996657]
Dimmock, J.R.; Das, U. Antineoplastic compounds. US Patent 7,582,655B2. 2009.
Thakral, S.; Singh, V. Recent development on importance of heterocyclic amides as potential bioactive molecules: a review. Curr. Bioact. Compd., 2019, 15(3), 316-336.
Pratt, W.B.; Ruddon, R.W. The anticancer drugs; Oxford University Press: New York, 1979, p. 273.
[ 10.1002/jps.2600690439]
Boyd, M.R.; Paull, K.D. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev. Res., 1995, 34(2), 91-109.
Das, U.; Sakagami, H.; Chu, Q.; Wang, Q.; Kawase, M.; Selvakumar, P.; Sharma, R.K.; Dimmock, J.R. 3,5-Bis-(benzylidene)-1-[4-2-(morpholin-4-yl)ethoxyphenylcarbon-yl]-4-piperidone hydrochloride: a lead tumor-specific cytotoxin which induces apoptosis and autophagy. Bioorg. Med. Chem. Lett., 2010, 20(3), 912-917.
[] [PMID: 20064715]
Robles-Escajeda, E.; Das, U.; Ortega, N.M.; Parra, K.; Francia, G.; Dimmock, J.R.; Varela-Ramirez, A.; Aguilera, R.J. A novel curcumin-like dienone induces apoptosis in triple-negative breast cancer cells. Cell Oncol. (Dordr.), 2016, 39(3), 265-277.
[] [PMID: 26920032]
Edraki, N.; Das, U.; Hemateenejad, B.; Dimmock, J.R.; Miri, R. Comparative QSAR analysis of 3,5-bis (Arylidene)-4-piperidone derivatives: the development of predictive cytotoxicity models. Iran. J. Pharm. Res., 2016, 15(2), 425-437.
[PMID: 27642313]
Das, S.; Gul, H.I.; Das, U.; Balzarini, J.; Dimmock, S.G.; Dimmock, J.R. Novel conjugated unsaturated ketones with submicromolar potencies towards some leukemic and colon cancer cells. Med. Chem., 2019, 15(4), 430-438.
[] [PMID: 30324886]
Sheshkin, D. Handbook of parametric and non-parametric statistical procedures, 2nd ed; Chapman and Hall: London, 2000, pp. 1093-1107.
Helal, M.; Das, U.; Bandy, B.; Islam, A.; Nazarali, A.J.; Dimmock, J.R. Mitochondrial dysfunction contributes to the cytotoxicity of some 3,5-bis(benzylidene)-4-piperidone derivatives in colon HCT-116 cells. Bioorg. Med. Chem. Lett., 2013, 23(4), 1075-1078.
[] [PMID: 23305919]
Contreras, L.; Calderon, R.I.; Varela-Ramirez, A.; Zhang, H.Y.; Quan, Y.; Das, U.; Dimmock, J.R.; Skouta, R.; Aguilera, R.J. Induction of apoptosis via proteasome inhibition in leukemia/lymphoma cells by two potent piperidones. Cell Oncol. (Dordr.), 2018, 41(6), 623-636.
[] [PMID: 30088262]
Das, S.; Das, U.; Bandy, B.; Gorecki, D.K.; Dimmock, J.R. The effect of some 1-[4-(2-diethylaminoethoxy)-phenylcarbonyl]-3,5-bis (benzylidene)-4-piperidone methiodides and related compounds on respiration and swelling of rat liver mitochondria. Pharmazie, 2008, 63(11), 827-829.
[PMID: 19069245]
Das, U.; Selvakumar, P.; Sharma, R.K.; Haas, T.A.; Dimmock, J.R. N-acyl-3,5-bis(arylidene)-4-piperidones and related compounds which stimulate fyn kinase. J. Enzyme Inhib. Med. Chem., 2007, 22(4), 451-455.
[] [PMID: 17847712]
Aronov, A.M.; Murcko, M.A. Toward a pharmacophore for kinase frequent hitters. J. Med. Chem., 2004, 47(23), 5616-5619.
[] [PMID: 15509160]
Levitzki, A.; Gazit, A. Tyrosine kinase inhibition: an approach to drug development. Science, 1995, 267(5205), 1782-1788.
[] [PMID: 7892601]
Singh, R.S.; Das, U.; Auschwitz, J.M.; Leed, S.E.; Hickman, M.R.; Dimmock, J.R.; Alcorn, J. From a cytotoxic agent to the discovery of a novel antimalarial agent. Bioorg. Med. Chem. Lett., 2013, 23(2), 584-587.
[] [PMID: 23228469]
Leonard, G.D.; Polgar, O.; Bates, S.E. ABC transporters and inhibitors: new targets, new agents. Curr. Opin. Investig. Drugs, 2002, 3(11), 1652-1659.
[PMID: 12476969]
Das, U.; Molnár, J.; Baráth, Z.; Bata, Z.; Dimmock, J.R. 1-[4-(2-Aminoethoxy)phenylcarbonyl]-3,5-bis-(benzylidene)-4-oxopiperidines: a novel series of highly potent revertants of P-glycoprotein associated multidrug resistance. Bioorg. Med. Chem. Lett., 2008, 18(12), 3484-3487.
[] [PMID: 18513966]
Chen, Y.; Pant, A.C.; Simon, S.M. P-glycoprotein does not reduce substrate concentration from the extracellular leaflet of the plasma membrane in living cells. Cancer Res., 2001, 61(21), 7763-7769.
Michel, D.; Chitanda, J.M.; Balogh, R.; Yang, P.; Singh, J.; Das, U.; El-Aneed, A.; Dimmock, J.; Verrall, R.; Badea, I. Design and evaluation of cyclodextrin-based delivery systems to incorporate poorly soluble curcumin analogs for the treatment of melanoma. Eur. J. Pharm. Biopharm., 2012, 81(3), 548-556.
[] [PMID: 22531300]
Poorghorban, M.; Das, U.; Alaidi, O.; Chitanda, J.M.; Michel, D.; Dimmock, J.; Verrall, R.; Grochulski, P.; Badea, I. Characterization of the host-guest complex of a curcumin analog with β-cyclodextrin and β-cyclodextrin-gemini surfactant and evaluation of its anticancer activity. Int. J. Nanomedicine, 2015, 10, 503-515.
[]] [PMID: 25609956]
Singh, R.S.; Das, U.; Dimmock, J.R.; Alcorn, J. A general HPLC-UV method for the quantitative determination of curcumin analogues containing the 1,5-diaryl-3-oxo-1,4-pentadienyl pharmacophore in rat biomatrices. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2010, 878(28), 2796-2802.
[] [PMID: 20863771]
Awad, H.; Stoudemayer, M.J.; Usher, L.; Amster, I.J.; Cohen, A.; Das, U.; Whittal, R.M.; Dimmock, J.; El-Aneed, A. The unexpected formation of [M - H]+ species during MALDI and dopant-free APPI MS analysis of novel antineoplastic curcumin analogues. J. Mass Spectrom., 2014, 49(11), 1139-1147.
[] [PMID: 25395129]
McNaney, C.A.; Drexler, D.M.; Hnatyshyn, S.Y.; Zvyaga, T.A.; Knipe, J.O.; Belcastro, J.V.; Sanders, M. An automated liquid chromatography-mass spectrometry process to determine metabolic stability half-life and intrinsic clearance of drug candidates by substrate depletion. Assay Drug Dev. Technol., 2008, 6(1), 121-129.
[] [PMID: 18336089]
Das, U.; Das, S.; Bandy, B.; Stables, J.P.; Dimmock, J.R. N-Aroyl-3,5-bis(benzylidene)-4-piperidones: a novel class of antimycobacterial agents. Bioorg. Med. Chem., 2008, 16(7), 3602-3607.
[] [PMID: 18282710]
Stables, J.P.; Kupferberg, H.J. The NIH anticonvulsant drug development (ADD) program: preclinical anticonvulsant screening project.In:Molecular and Cellular Targets for Anti-epileptic Drugs; Avanzini, G.; Regesta, G.; Tanganelli, P.; Avoli, M., Eds.; John Sibbey: London, 1997, pp. 191-198.
Das, U.; Singh, R.S.; Alcorn, J.; Hickman, M.R.; Sciotti, R.J.; Leed, S.E.; Lee, P.J.; Roncal, N.; Dimmock, J.R. 3,5-bis(benzylidene)-4-piperidones and related N-acyl analogs: a novel cluster of antimalarials targeting the liver stage of Plasmodium falciparum. Bioorg. Med. Chem., 2013, 21(23), 7250-7256.
[] [PMID: 24139941]

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy